Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474083 · ClinicalTrials.gov registry record · Phase 1
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
A Phase 1 study, sponsored by vTv Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 248
- Enrollment target
NCT01474083 is a Phase 1 study that has completed, run by vTv Therapeutics. The registered enrollment target is 248 participants.
The verdict
NCT01474083, a Phase 1 study, has completed, sponsored by vTv Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 248 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the drug levels and biomarkers in the body and the safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the study will receive placebo for 1 week followed by 1 of 4 treatments for 6 weeks. One of the 4 treatments will be placebo, which does not contain an active ingredient. The study participation includes in-patient and out-patient days.
Interventions
- DRUG Placebo
- DRUG GK1-399 (formerly TTP399)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01474083
The ClinicalTrials.gov registry entry for NCT01474083 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01474083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01474083 about?
NCT01474083 is a clinical study titled "A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes". The purpose of this trial is to study the drug levels and biomarkers in the body and the safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the study will receive placebo for 1 week followed by 1 of 4 treatments for 6 weeks. One of the 4 treatments will be plac...
What is the current status of trial NCT01474083?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2011-11. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01474083?
The interventions under investigation include: Placebo (DRUG), GK1-399 (formerly TTP399) (DRUG).
Who is sponsoring clinical trial NCT01474083?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.